PCSK9 and hemorrhagic stroke: Ezetimibe plus statins was the most likely regimen to cause hemorrhagic stroke compared to placebo (RR: 2.87, 95% CrI: 0.64-15.33; SUCRA: 0.82), followed by statins alone (RR: 1.57, 95% CrI: 1.13-2.21; SUCRA: 0.57) and PCSK9 inhibitors plus statins (RR: 1.56, 95% CrI: 0.69-3.56; SUCRA: 0.53).